반응식
Cl.[I:2][C:3]1[CH:8]=[CH:7][C:6]([NH:9]N)=[CH:5][CH:4]=1.[F:11][C:12]1[CH:20]=[CH:19][CH:18]=[CH:17][C:13]=1[CH2:14][CH2:15]Br.C(N(CC)CC)C.Cl.[CH3:29][N:30]1[CH2:35][CH2:34][C:33](=O)[CH2:32][CH2:31]1.FC(F)(F)C([O-])=O>C(O)C>[F:11][C:12]1[CH:20]=[CH:19][CH:18]=[CH:17][C:13]=1[CH2:14][CH2:15][N:9]1[C:6]2[CH:7]=[CH:8][C:3]([I:2])=[CH:4][C:5]=2[C:32]2[CH2:31][N:30]([CH3:29])[CH2:35][CH2:34][C:33]1=2참가 물질
7
반응물 5
생성물 1
시약·촉매·용매 1
실험 절차
Preparation of the title compound was carried out according to General Method 8. 4-Iodophenylhydrazine hydrochloride (500 mg, 2.1 mmol), 2-fluorophenethylbromide (0.3 ml, 2.1 mmol), triethyl amine (0.8 ml, 6.3 mmol) and N-methyl-4-piperidone hydrochloride (312 mg, 2.1 mmol) were taken in ethanol (10 ml) to obtain 5 mg of 5-(2-fluorophenethyl)-2,3,4,5-tetrahydro-8-iodo-2-methyl-1H-pyrido[4,3-b]indole as a trifluoroacetate salt after purification by reverse-phase chromatography (C-18, 500 mm×50 mm, Mobile Phase A=0.05% TFA in water, B=0.05% TFA in acetonitrile, Gradient: 10% B to 80% B in 30 min, injection vol. 5 mL).
출처 및 근거
- ORD 기록
- ord-4270a7d833da43d7bc15e89da1c0c1e8
- 출처 데이터셋
- uspto-grants-2012_12
- 특허 번호
- US08338408B2
연결된 노트
불러오는 중…